Article
Gastroenterology & Hepatology
Giorgina Mieli-Vergani, Sanjay Bansal, James F. Daniel, Aydan Kansu, Deirdre Kelly, Carmen Martin, Sarah Tizzard, Stefan Wirth, Julian Zhou, Diego Vergani
Summary: In children and adolescents with immune-tolerant CHB, antiviral therapy was found to be ineffective in achieving hepatitis B surface antigen loss, as evaluated in this trial.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2021)
Article
Gastroenterology & Hepatology
Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Chun-Jen Liu, Ching-Chu Lo, Ke-Jhang Huang, Jyh-Jou Chen, Kuo-Chih Tseng, Chi-Yang Chang, Cheng-Yuan Peng, Yu-Lueng Shih, Chia-Sheng Huang, Wei-Yu Kao, Sheng-Shun Yang, Ming-Chang Tsai, Jo-Hsuan Wu, Po-Yueh Chen, Pei-Yuan Su, Jow-Jyh Hwang, Yu-Jen Fang, Pei-Lun Lee, Chi-Wei Tseng, Fu-Jen Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chun-Chao Chang, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao
Summary: A study conducted in Taiwan showed that the treatment with SOF/VEL plus RBV for 12 weeks is highly effective and well-tolerated for patients with Child-Pugh B/C HCV-related cirrhosis. The SVR12 rates were outstanding, reaching 100%, and patients experienced improvements in liver and kidney function.
CLINICAL AND MOLECULAR HEPATOLOGY
(2021)
Article
Virology
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hezode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Samuel
Summary: The study demonstrated that SOF/VEL plus RBV therapy for 12 weeks in patients with HCV-associated decompensated cirrhosis achieved high SVR12 rates and was generally well tolerated.
Article
Immunology
Milan J. Sonneveld, Bettina E. Hansen, Willem P. Brouwer, Henry L-Y Chan, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Rong-Nan Chien, Robert J. de Knegt, Cynthia Wat, Vedran Pavlovic, Anuj Gaggar, Qing Xie, Maria Buti, Robert A. de Man, Harry L. A. Janssen
Summary: This study investigated the relationship between HBsAg levels and hepatic fibrosis and cirrhosis in patients with chronic hepatitis B. The results showed that lower HBsAg levels were associated with higher rates of fibrosis and cirrhosis in HBeAg-positive patients, but not in HBeAg-negative patients. Additionally, genotype-specific HBsAg cutoffs could be used to rule out the presence of cirrhosis. These findings are important for the diagnosis and treatment of chronic hepatitis B patients.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Multidisciplinary Sciences
Hyun Young Woo, Jeong Heo, Won Young Tak, Heon Ju Lee, Woo Jin Chung, Jung Gil Park, Soo Young Park, Young Joo Park, Yu Rim Lee, Jae Seok Hwang, Young Oh Kweon
Summary: This study found that in patients with chronic hepatitis B who had received long-term nucleos(t)ide analogue therapy, switching to peginterferon alfa-2a for 48 weeks significantly reduced HBsAg levels and increased HBeAg seroconversion compared to patients who continued on nucleos(t)ide analogue therapy.
Article
Medicine, General & Internal
I-Cheng Lee, Chien-Wei Su, Keng-Hsin Lan, Yuan-Jen Wang, Kuei-Chuan Lee, Han-Chieh Lin, Ming-Chih Hou, Yi-Hsiang Huang
Summary: For HBeAg-negative CHB patients, baseline serum CXCL9 and HBsAg levels can predict HBsAg loss after PegIFN therapy. Combining virological and immunological biomarkers can predict the long-term outcomes of PegIFN therapy.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2021)
Article
Pharmacology & Pharmacy
Xiaoyun Peng, Longgui Chen, Mingying Xiao
Summary: The purpose of this study was to investigate the efficacy of entecavir plus peginterferon alfa-2a in the treatment of lamivudine-resistant chronic hepatitis B (CHB) patients with different genotypes. The results showed that at the 6th and 12th month of follow-up, CHB patients with genotype B had significantly higher HBV-DNA clearance rate, ALT normalization rate, and HBeAg seroconversion rate compared to patients with genotype C (p < 0.05). There were no significant differences between the two groups in these rates at the 18th and 24th month of follow-up (p > 0.05). The quality of life (QOL) of the patients differed between the two groups (p < 0.05). Genotype B CHB patients are more suitable for this combination protocol.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
(2023)
Article
Infectious Diseases
Ran Cheng, Ning Tan, Hao Luo, Qian Kang, Xiaoyuan Xu
Summary: Sequential algorithms based on APRI, FIB-4, and TE can significantly reduce the need for liver biopsy and provide accurate diagnosis of advanced fibrosis and cirrhosis in patients with CHB.
INFECTION AND DRUG RESISTANCE
(2023)
Review
Zoology
Jia Shi
Summary: This study aimed to evaluate the response rate of HBeAg negative chronic hepatitis patients to Peginterferon alfa-2a treatment. The results showed that patients with C genotype had a higher treatment response rate compared to those with D genotype. However, using Peginterferon alfa-2a alone as treatment is not ideal due to the low response rate.
PAKISTAN JOURNAL OF ZOOLOGY
(2021)
Article
Medicine, General & Internal
Yoonseok Lee, Seryun Bae, Ji Hoon Kim, Minjung Kwak, So Yeon Jeon, Taehyung Kim, Sun Young Yim, Young-Sun Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
Summary: This study evaluated the diagnostic efficacy of serum Asialo alpha 1-acid glycoprotein (AsAGP) levels in classifying the severity of liver fibrosis in patients with chronic hepatitis B (CHB) and distinguishing them from healthy controls. The results showed significant differences in serum AsAGP levels between the CHB group, healthy control group, and CHB with liver cirrhosis group. Serum AsAGP levels were also positively correlated with liver stiffness. Therefore, serum AsAGP levels may serve as a potential biomarker for predicting the progression of liver disease in CHB.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Nicole J. Kim, Philip Vutien, Erin Cleveland, Anne Cravero, George N. Ioannou
Summary: Pooled estimates from meta-analysis showed that the incidence of hepatocellular carcinoma (HCC) after sustained virologic response (SVR) in patients with cirrhosis was very high (2.99/100 person-years). However, this incidence may decline with longer time after SVR. In patients without cirrhosis, including those with F3 fibrosis, the incidence of HCC was lower than the thresholds for cost-effective HCC screening. There was little heterogeneity among studies in patients with F3 fibrosis, suggesting that HCC screening may not be warranted.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Olympia E. Anastasiou, Florin A. Caruntu, Manuela G. Curescu, Kendal Yalcin, Ulus S. Akarca, Selim Gurel, Stefan Zeuzem, Andreas Erhardt, Stefan Lueth, George V. Papatheodoridis, Onur Keskin, Kerstin Port, Monica Radu, Mustafa K. Celen, Ramazan Idilman, Benjamin Heidrich, Ingmar Mederacke, Heiko von der Leyen, Julia Kahlhoefer, Maria von Karpowitz, Svenja Hardtke, Markus Cornberg, Cihan Yurdaydin, Heiner Wedemeyer
Summary: This study confirms that patients who undergo PEG-IFNa treatment and achieve HDV suppression have a lower risk of developing liver-related complications. Until alternative therapies become available, PEG-IFNa treatment should be recommended for patients with HDV infection.
LIVER INTERNATIONAL
(2023)
Review
Gastroenterology & Hepatology
Ming-Lun Yeh, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang
Summary: Baseline factors and on-treatment viral kinetics can predict the response to Peg-IFNα therapy for CHB patients, leading to tailored therapeutic strategies and potentially better treatment outcomes.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Lung-Yi Mak, Danny Ka-Ho Wong, Ka-Shing Cheung, Rex Wan-Hin Hui, Fen Liu, James Fung, Wai-Kay Seto, Man-Fung Yuen
Summary: The study found that high serum M2BPGi and central obesity were associated with an increased risk of persistent advanced fibrosis or cirrhosis in patients with chronic hepatitis B infection, despite potent antiviral therapy.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Medicine, General & Internal
Akito Nozaki, Makoto Chuma, Koji Hara, Satoshi Moriya, Hiroyuki Fukuda, Kazushi Numata, Katsuaki Tanaka, Manabu Morimoto, Kentaro Sakamaki, Takeharu Yamanaka, Masaaki Kondo, Shin Maeda
Summary: Oral direct-acting antiviral (DAA) treatment for HCV infection can lead to regression of fibrosis in patients who achieved sustained virological response (SVR). M2BPGi showed good correlation with other fibrosis markers and had diagnostic value at week 48 after treatment initiation.
Article
Pharmacology & Pharmacy
Savino Bruno, Alex J. Thompson, Rosina Critelli, Andrea Crosignani, Sonia Rossi, Stefania De Lisi, Elisabetta Cariani, Paola Zermiani, Valentina Vaira, Vincenzo Boccaccio, Patrick Maisonneuve, Erica Villa
ANTIVIRAL RESEARCH
(2015)
Article
Surgery
Roberto Santambrogio, Matteo Barabino, Savino Bruno, Mara Costa, Andrea Pisani Ceretti, Maria Rachele Angiolini, Massimo Zuin, Franca Meloni, Enrico Opocher
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2016)
Article
Gastroenterology & Hepatology
Salvatore Petta, Giuseppe Cabibbo, Marco Enea, Fabio Salvatore Macaluso, Antonella Plaia, Raffaele Bruno, Antonio Gasbarrini, Savino Bruno, Antonio Craxi, Calogero Camma
DIGESTIVE AND LIVER DISEASE
(2014)
Article
Gastroenterology & Hepatology
Michael P. Manns, John M. Vierling, Bruce R. Bacon, Savino Bruno, Oren Shibolet, Yaacov Baruch, Patrick Marcellin, Luzelena Caro, Anita Y. M. Howe, Christine Fandozzi, Jacqueline Gress, Christopher L. Gilbert, Peter M. Shaw, Michael P. Cooreman, Michael N. Robertson, Peggy Hwang, Frank J. Dutko, Janice Wahl, Niloufar Mobashery
Article
Gastroenterology & Hepatology
Simone Saibeni, Maria J. Etchevers, Dolors Tassies, Julian Panes, Joan C. Reverter, Silvio Danese, Josep M. Pique, Savino Bruno, Maurizio Vecchi, Antonio Gasbarrini, Miquel Sans
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2013)
Letter
Medicine, General & Internal
Patrick Maisonneuve, Savino Bruno
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2013)
Letter
Gastroenterology & Hepatology
Savino Bruno, Alessandra Mangia
JOURNAL OF HEPATOLOGY
(2013)
Article
Gastroenterology & Hepatology
Savino Bruno, John M. Vierling, Rafael Esteban, Lisa M. Nyberg, Hugo Tanno, Zachary Goodman, Fred Poordad, Bruce Bacon, Keith Gottesdiener, Lisa D. Pedicone, Janice K. Albrecht, Clifford A. Brass, Seth Thompson, Margaret H. Burroughs
JOURNAL OF HEPATOLOGY
(2013)
Editorial Material
Gastroenterology & Hepatology
Tarik Asselah, Savino Bruno, Antonio Craxi
JOURNAL OF HEPATOLOGY
(2014)
Article
Gastroenterology & Hepatology
John M. Vierling, Stefan Zeuzem, Fred Poordad, Jean-Pierre Bronowicki, Michael P. Manns, Bruce R. Bacon, Rafael Esteban, Steven L. Flamm, Paul Y. Kwo, Lisa D. Pedicone, Weiping Deng, Frank J. Dutko, Mark J. DiNubile, Kenneth J. Koury, Frans A. Helmond, Janice Wahl, Savino Bruno
JOURNAL OF HEPATOLOGY
(2014)
Article
Gastroenterology & Hepatology
S. Bruno, S. Bollani, A. L. Zignego, J. M. Pascasio, C. Magni, A. Ciancio, M. Caremani, A. Mangia, S. Marenco, S. Piovesan, L. Chemello, S. Babudieri, A. Moretti, F. Gea, C. Colletta, R. Perez-Alvarez, X. Forns, J. R. Larrubia, J. Arenas, J. Crespo, V. Calvaruso, F. Ceccherini Silberstein, P. Maisonneuve, A. Craxi, J. L. Calleja
JOURNAL OF VIRAL HEPATITIS
(2015)
Article
Gastroenterology & Hepatology
Michael P. Manns, Jonathan McCone, Mitchell N. Davis, Lorenzo Rossaro, Eugene Schiff, Mitchel L. Shiffman, Bruce Bacon, Marc Bourliere, Mark S. Sulkowski, Savino Bruno, Luis Balart, Jean-Pierre Bronowicki, Paul Kwo, Fred Poordad, Franco Felizarta, K. Rajender Reddy, Frans A. Helmond, Heather L. Sings, Lisa D. Pedicone, Margaret Burroughs, Clifford A. Brass, Janice K. Albrecht, John M. Vierling
LIVER INTERNATIONAL
(2014)
Review
Gastroenterology & Hepatology
Vincenzo Boccaccio, Savino Bruno
LIVER INTERNATIONAL
(2014)
Review
Gastroenterology & Hepatology
Vincenzo Boccaccio, Savino Bruno
LIVER INTERNATIONAL
(2015)
Article
Gastroenterology & Hepatology
Antonio Ascione, Savino Bruno, Carmine Coppola, Alessandra Mangia, Alessandra Orlandini, Manuela Schmitz, Barbara Deodato, Massimo Puoti
HEPATO-GASTROENTEROLOGY
(2014)